Meningioma recurrence rates following treatment: a systematic analysis

Cheung, Victor; Kim, Albert; Sahgal, Arjun; Das, Sunit

doi:10.1007/s11060-017-2659-6

Cited by 45 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is also a role for SRS to treat low grade meningiomas and previously radiated meningiomas to improve PFS ( 45 , 46 ). In a recent review of the literature evaluating meningioma recurrence after surgery, recurrence rates ranged from 0–22.5% at 5 years for grade I meningiomas, 15% at 2 years, and 37% of patients over 10 years for grade II meningiomas ( 47 ). PFS and overall survival (OS) rates of patients with grade III meningiomas has been reported to range from 0–57% and 33–61% at 5 years, respectively ( 46 , 48 , 49 ).…”

Section: Current Management Options For Meningiomasmentioning

confidence: 99%

Basis for Immunotherapy for Treatment of Meningiomas

et al. 2020

View full text Add to dashboard Cite

Meningiomas are common tumors that account for approximately one third of CNS tumors diagnosed every year. They are classified by the World Health Organization in grades I-III. Higher grades have an increased rate of growth, invasiveness, rate of recurrence, and worse outcomes than lower grades. Most meningiomas are grade I, while ~18% of meningiomas are grade II and III in hospital-based series. Meningiomas are typically “benign” tumors that are treated with surgery and radiation. However, when they recur or are unresectable, treatment options are very limited, especially since they are chemotherapy-resistant. Recent advances in the treatment of cancers with immunotherapy have focused on checkpoint blockade as well as other types of immunotherapy. There is emerging evidence supporting the use of immunotherapy as a potentially effective treatment strategy for meningioma patients. The immune microenvironment of meningiomas is a complex interplay of genetic alterations, immunomodulatory protein expression, and tumor-immune cell interactions. Meningiomas are known to be infiltrated by immune cells including microglia, macrophages, B-cells, and T-cells. Several mechanisms contribute to decreased an ti-tumor immune response, allowing tumor growth and evasion of the immune system. We discuss the most current knowledge on the immune micro-environment of meningiomas, preclinical findings of immunotherapy in meningiomas, meningioma immunotherapy clinical trials, and also offer insight into future prospects for immunotherapies in meningiomas.

show abstract

Section: Current Management Options For Meningiomasmentioning

confidence: 99%

Basis for Immunotherapy for Treatment of Meningiomas

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A systematic review explains that the grade of meningioma can affect the rate of recurrence among clients. Recurrence rates range from 0.00 to 2.36 per 100 people per year for WHO grade I meningiomas and 7.35 -11.46 per 100 people per year for WHO class II meningioma, which will certainly affect the quality of life of clients (Lam Shin Cheung et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

The Quality of Life and Associated Factors in Indonesian Meningioma Clients after Surgery: A Cross-Sectional Study

Ganefianty

Irawati

Dahlia

et al. 2021

DCID

View full text Add to dashboard Cite

show abstract

“…Meningioma is the most common primary central nervous system tumor originating from meningothelial cells (1,2). Despite its genetic landscape having been well characterized over the years, we still lack speci c biomarkers and drug targets (33)(34)(35)(36). Higher-grade meningiomas have signi cant morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

miR-9-1 Is a New Circulating Biomarker for Higher-grade Meningioma Regulated via the EGFR-FOS Network

Daniele¹,

Negroni²,

Ferluga³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Meningiomas are the most common primary CNS tumors. According to the World Health Organization Classification (WHO), they are classified as benign (grade I), atypical (grade II), and anaplastic/malignant (grade III). Chemotherapy has proven ineffective in treating these tumors, which are primarily managed by surgery, radiotherapy, or a combination of them. Morbidity and mortality correlate with meningioma grade. Currently, risk assessment for treatment is based on the radiological assessment of tumor size, tumor growth rate, and/or clinical progression of symptoms. Methods: We performed a cancer miRNA array in an in vitro model of meningioma in order to identify circulating biomarkers in meningioma patients. We validated the miRNA biomarker candidate in cells and tissues and analyzed its regulation. We then investigated expression in tissues and blood. Results: We identified miR-9-1 as significantly overexpressed in atypical and anaplastic cells compared to benign. We further demonstrated that miR-9-1 overexpression is due to increased levels of FOS via upregulation of the EGFR receptor, and showed that miR-9-1 and FOS are upregulated in a cohort of higher-grade meningioma biopsies. Next, we isolated circulating exosomes from meningioma patients’ serum samples, and found higher levels of miR-9-1 in higher-grade compared to low-grade meningiomas patients. Conclusions: Overall, our study shows overexpression and the mechanism of miR-9-1 regulation and suggests miR-9-1 as a novel circulating biomarker candidate to identify tumor grade in meningioma.

show abstract

Meningioma recurrence rates following treatment: a systematic analysis

Cited by 45 publications

References 32 publications

Basis for Immunotherapy for Treatment of Meningiomas

Basis for Immunotherapy for Treatment of Meningiomas

The Quality of Life and Associated Factors in Indonesian Meningioma Clients after Surgery: A Cross-Sectional Study

miR-9-1 Is a New Circulating Biomarker for Higher-grade Meningioma Regulated via the EGFR-FOS Network

Contact Info

Product

Resources

About